• Earlier in August 2026, Lowey Dannenberg filed the first consumer class action against Hims & Hers Health following an FTC-led civil enforcement complaint alleging misleading “free consultation” offers, problematic subscription practices, and improper sharing of sensitive health data with advertisers.
• On top of these legal and regulatory actions, an advertising review body has pushed Hims & Hers to alter several product claims, sharpening investor focus on the company’s compliance, marketing practices, and data privacy controls.
• Next, we’ll examine how rising regulatory and legal scrutiny around Hims & Hers’ privacy and subscription practices may reshape its investment narrative.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Hims & Hers Health Investment Narrative Recap

To own Hims & Hers, you need to believe in scalable digital care, strong subscription engagement, and trust around sensitive health data. The FTC action and follow-on class suit, paired with advertising claim changes, sharpen the key near term catalyst and risk: whether the company can sustain user and revenue momentum while overhauling privacy, subscription flows, and marketing practices. If customer trust or acquisition efficiency weakens from regulatory remedies, that would be a material overhang.

The recent National Advertising Division decision is particularly tied to this backdrop. While it upheld some efficacy framing, it recommended modifying or dropping certain safety and endorsement claims, which Hims & Hers agreed to do. For a business that leans heavily on direct response advertising to support growth in weight loss and sexual health offerings, these changes intersect directly with the core catalyst of marketing-driven expansion and the risk of rising acquisition and compliance costs.

Yet beneath the growth story, investors should be aware that mounting privacy and subscription scrutiny could force lasting changes to how Hims & Hers acquires and retains customers...

Hims & Hers Health's narrative projects $5.6 billion revenue and $211.5 million earnings by 2029. This requires 33.0% yearly revenue growth and a $224.7 million earnings increase from -$13.2 million today.

Uncover how Hims & Hers Health's forecasts yield a $28.42 fair value, a 10% downside to its current price.

Exploring Other Perspectives

By contrast, the most pessimistic analysts were already cautious, expecting about US$4.3 billion in 2029 revenue and US$218 million in earnings, and this new regulatory heat could easily push those expectations even lower, so it is worth comparing these scenarios and deciding which risks you think matter most.

Explore 22 other fair value estimates on Hims & Hers Health - why the stock might be worth 26% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Hims & Hers Health research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Hims & Hers Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hims & Hers Health's overall financial health at a glance.

Searching For A Fresh Perspective?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.